← Back to feedRead original →
VERIFIEDET Finance·positive
Zydus Therapeutics' saroglitazar drug granted priority review by US FDA
AI Summary
- ·Zydus Therapeutics' drug saroglitazar has received priority review from the US FDA.
- ·The drug is intended for the treatment of primary biliary cholangitis, a liver disease.
- ·Zydus Therapeutics plans to launch saroglitazar in the US in the fourth quarter of fiscal year 2027.